While the FDA has been in the news for a handful of approvals over the past year-plus, New York dermatologist Bruce Katz, MD, and his colleagues, are โ€œbeyond excitedโ€ for the administrationโ€™s upcoming consent in the field of aesthetics.

Enter DAXI, a neuromodulator that Dr. Katz explains is โ€œlike Botox, except it lasts longer, with a time span averaging around 24 weeks.โ€

Read the full article at www.newbeauty.com